Novavax sees weak Covid vaccine sales

Novavax cuts 2024 revenue forecast again on lower COVID vaccine sales
Nov 12 (Reuters) - Novavax (NVAX.O), opens new tab cut its annual revenue forecast on Tuesday, citing lower-than-expected sales of its COVID-19 vaccine, ahead of handing over the rights to sell the shot to French drugmaker Sanofi (SASY.PA), opens new tab.
Novavax sees weak Covid vaccine sales, convinced Sanofi can do better
Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals and a pipeline of new vaccines it's now evaluating for R&D.
FDA clears Novavax to resume trials of Covid-19 and flu combo vaccine
Novavax has received the green light from the US Food and Drug Administration (FDA) to resume clinical trials for its Covid-19 and influenza combination vaccine (CIC) and standalone influenza vaccines after a month-long clinical hold.
FDA lifts clinical hold on Novavax's combo COVID-flu shot
The Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its standalone flu vaccines after identifying a safety concern.
Novavax to Move Forward With Covid-19-Flu Vaccine After FDA Lifts Clinical Hold -- Update
Novavax is already poised to benefit from a separate combined Covid-flu vaccine via a deal with Sanofi announed earlier this year. Under the $1.4 billion co-licensing agreement, announced in May, Sanofi will have the sole right to use Novavax's existing Covid-19 vaccine in combination with its own flu vaccine.
Novavax falls after guidance cut on lower vaccine sales
Novavax (NVAX) stock falls 12% in premarket as company cuts full-year revenue guidance due to a lower sales outlook for its COVID-19 vaccine Nuvaxovid. Read more here.
Novavax: Navigating Fiscal Challenges and Strategic Shifts Amid COVID Vaccine Market Uncertainty
In a report released today, Brendan Smith from TD Cowen maintained a Hold rating on Novavax (NVAX – Research Report), with a price target ...
FiercePharma8d
Novavax coughs up $123.8M to settle COVID vaccine supply dispute with UK
Novavax has inked another settlement for a past COVID-19 vaccine supply deal. | Novavax has inked another settlement for a ...
Novavax Lowers 2024 Forecast Despite Q3 Revenue Beat, Stock Falls
Novavax reports Q3 2024 sales of $84.5 million, beating estimates, with a net loss of $121 million. EPS improves, FDA ...
Novavax Stock is Slipping After the Vaccine Maker Cut its Outlook Again
Novavax shares dropped Tuesday morning after the company slashed its full-year outlook when it announced its third-quarter results.
AOL2d
Novavax stock plunges after quarterly earnings, but company sees hope in licensing deals
Novavax's COVID-19 vaccine continues to be its only commercial product and currently has about 2%-3% market share, ...
Hosted on MSN1d
Novavax, Inc. (NASDAQ:NVAX) Q3 2024 Earnings Call Transcript
This strategy has already resulted in the Sanofi partnership we announced this year, which has enabled us to transition away ...
WPRI 121d
Don’t wait for a holiday surge. Now is a good time to get your flu and COVID-19 vaccines
But COVID-19 tends to jump in the winter months ... The Pfizer and Moderna shots are formulated against a virus subtype ...
Yahoo Finance2d
Novavax: Stock plunges after quarterly earnings, but sees hope in licensing deals
Novavax's COVID-19 vaccine continues to be its only commercial product and currently has about 2%-3% market share, ...